13 results about "Antagomir" patented technology

The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.

The invention discloses an application and a preparation of a miR-125b-5p inhibitor or antagonist for treating and / or preventing myopia. According to the application, a miR-125b-5p inhibitor or antagonist, particularly miR-125b-5p antiagomir with a nucleotide sequence as shown in SEQ ID NO: 8, is used for inhibiting the expression of miR-125b-5p in sclera and increasing the expression of a target gene tp53, so that the transdifferentiation of sclera fibroblasts can be remarkably reduced, sclera remodeling can be reduced, and the diopter reduction and ocular axis extension of guinea pig deprivation myopia can be retarded; the composition can be used for preventing myopia and controlling myopia progress, has the advantages of low administration frequency and high safety, and provides a safer, more effective and more convenient prevention and control means for myopia patients, especially teenagers.

The invention relates to negative functional modulators of at least one variant of the non-erythrogenic erythropoietin (V-EPO) and pharmaceutical compositions or kits containing them. Such functional negative modulators of V-EPO may be a mono- or multi-specific antibody anti-EV3, anti-EV4, anti-EV1-4, anti-EV1-5, anti-EV1-1, or EV2-1, or anti-Epo receptor (EpoR) anti-EPHB4, anti-CSF2RB, an antisense oligonucleotide, DNA decoy, RNA decoy, a ribozyme, an antagomiR, a shRNA, LNA or siRNA.Several uses of these functional modulators are described, which have been advantageously employed as a medicament and for the treatment of an oncological pathology, a proliferative pathology, chronic inflammatory diseases on an autoimmune and non-autoimmune basis, of neurodegenerative diseases, and in the treatment of patients undergoing organ or tissue transplantation.The invention also describes variants of EPO for use in the diagnosis and in the treatment of an oncological pathology, a proliferative pathology, chronic inflammatory diseases on an autoimmune and non-autoimmune basis, of neurodegenerative diseases, and in the treatment of patients undergoing an organ or tissue transplantation and as a diagnostic agent.According to another aspect, a monoclonal antibody to at least one of the variants of the erythropoietin is described.According to yet another aspect, the use of at least one alternative splicing variant of non-erythrogenic EPO and the measurement thereof at tissue and / or systemic level is described, as well as the study of the methylation status of the promoters of the genes involved in the EPO signalling pathway (by way of example EPO, EPOR, EPHB4, CSF2RB), as diagnostic, prognostic and predictive markers of an oncological pathology, a proliferative pathology, neurodegenerative or inflammatory pathology.

The present invention relates to the combination of a miR-17mimic and a miR-340 mimic for use for the prevention and / or treatment of cancer, in particular for the treatment of glioblastoma. In particular, said combination additionally comprises a miR-222 antagomiR.

The invention discloses an application of a bone marrow mesenchymal stem cell outer vesicle for inhibiting miR-221-3p and a preparation method of the bone marrow mesenchymal stem cell outer vesicle. Rat bone marrow mesenchymal stem cell outer vesicles (rBMSCs-EVs) are extracted, rBMSCs-EVs (miR-221-3pin-EVs are used for cells, and antiagomiR-221-3p-EVs are used for animals) for inhibiting miR-221-3p are prepared, and in-vitro osteogenic induction differentiation experiments define that the miR-221-3pin-EVs can remarkably inhibit fluorine-induced osteogenic differentiation enhancement. Meanwhile, the fact that the antagomiR-221-3p-EVs can improve the phenomena of bone mineral density increase, bone trabecula number increase, bone trabecula thickening and the like of a sclerotic bone fluorosis rat model in vivo is further proved, and the antagomiR-221-3p-EVs has important significance on clinical treatment of a patient with the bone fluorosis.

The invention belongs to the technical field of biology, and particularly relates to related tRF for detecting hypertrophic cardiomyopathy and a detection method and application thereof. The invention provides a marker for hypertrophic cardiomyopathy, the marker is CHAtRF, and the nucleotide sequence of the marker is as shown in SEQ ID NO: 1. The CHAtRF antisense nucleotide CHAtRF antiagomir can be used as an active ingredient in a product for treating hypertrophic cardiomyopathy. By using the CHAtRF antiagomir, the expression of CHAtRF in the heart can be inhibited, pathological myocardial hypertrophy can be remarkably inhibited, the fibrosis area can be reduced, and the effect of improving the heart function can be achieved, so that the purpose of preparing the medicine for preventing and / or treating hypertrophic cardiomyopathy by using the CHAtRF antiagomir as a novel gene therapy technology is achieved; and a new drug action target is provided for treatment of heart diseases related to hypertrophic cardiomyopathy.

The application discloses a kind of miR-335-3p antagomir rhubarb hydrogel and its preparation method and application, belong to medical technical field.The application is first with rhubarb, sodium alginate and crosslinking agent by self-assembly to form three-dimensional network structure, then miR-335-3p antagomir is loaded in three-dimensional network structure, obtains miR-335-3p antagomir rhubarb hydrogel.MiR-335-3p antagomir in miR-335-3p antagomir rhubarb hydrogel and rhubarb can exert synergistic effect, significantly reduce acute pancreatitis, curative effect is superior to single drug.Meanwhile, miR-335-3p antagomir rhubarb hydrogel can realize drug sustained-release function.In addition, the composition of miR-335-3p antagomir rhubarb hydrogel can realize in-vivo metabolism and is non-toxic, non-accumulation, and high safety.

The invention belongs to the technical field of biology, and particularly relates to related tRF for detecting myocardial ischemia injury and a detection method and application thereof. The invention provides a marker for myocardial ischemic injury, the marker is CIAtRF, and the nucleotide sequence of the CIAtRF is as shown in SEQ ID NO: 1. The expression of CIAtRF is up-regulated during myocardial injury, and CIAtRF participates in regulation and control of myocardial ischemic injury. The CIAtRF antiagomir provided by the invention can be used as an active ingredient in a product for treating myocardial ischemia reperfusion injury. By using the CIAtRF antiagomir, the expression of CIAtRF in the heart can be inhibited, the myocardial infarction area can be obviously inhibited, the fibrosis area can be reduced, and the survival rate of myocardial cells can be increased, so that myocardial ischemic injury is relieved, and the effect of improving the cardiac function is realized.

A method for sensitizing a cancer chemotherapy drug includes: transfecting a cancer cell with an antisense oligonucleotide (e.g., siRNA-1976 or antagomir-1976) to form a transgenic cancer cell, thereby blocking the subsequent effects of miR-1976; and applying a cancer composition to the transgenic cancer cell, at which point the transgenic cancer cell has been blocked from the subsequent effects of miR-1976, and because the transgenic cancer cell has been blocked from the subsequent effects of miR-1976, the transgenic cancer cell develops a sensitivity to the cancer composition.

The present invention refers to a nucleic acid conjugate comprising at least one 2′,3′—O ketal moiety. This conjugate is suitable for the target-specific or target-selective delivery of nucleic acid molecules into cells such as mammalian cells including human cells with high efficacy. Thus, a new delivery vehicle for therapeutic nucleic acid molecules including antisense molecules. siRNA molecules, miRNA molecules, antagomirs or precursors of such molecules is provided.

A method of increasing sodium current in a cardiac cell generally includes introducing into the cardiac cell an miR-448 inhibitor in an amount effective to decrease miR-448 suppression of SCN5A mRNA transcription, thereby increasing sodium current in the cardiac cell. A method of increasing translation of SCN5A mRNA in a cell generally includes introducing into the cell an miR-448 inhibitor in an amount effective to decrease miR-448 suppression of SCN5A mRNA transcription. A method of decreasing arrythmia in a cardiac cell generally includes introducing into the cardiac cell an miR-448 inhibitor in an amount effective to decrease miR-448 suppression of SCN5A mRNA transcription. A method of treating arrythmia in a patient having, or at risk of having, arrythmia generally includes administering to the patient an miR-448 inhibitor in an amount effective to decrease the likelihood or extent of arrythmia in the patient. In some embodiments of all methods, the miR-448 inhibitor can be an miR-448 antagomir or an miR-448 sponge.

A newly discovered microRNA, hsa-miR-AMC1, serves as an early biomarker of coxsackievirus B4-induced type 1 diabetes. In addition, inhibiting hsa-miR-AMC1 may provide therapeutic benefits to type 1 diabetes patients. Trophoblast cells were also found to be a reliable model for identifying microRNAs that might be useful diagnostic markers or therapeutic targets for coxsackievirus B-induced type 1 diabetes